More Stories

Informist, Thursday, May 15, 2025

 

--Lupin Jan-Mar consol net profit INR 7.73 bln 

--Analysts saw Lupin Jan-Mar consol net profit INR 7.43 bln 

--Lupin Jan-Mar consol net profit INR 7.73 bln vs INR 3.59 bln year ago 

--Lupin Jan-Mar consol revenue INR 56.67 bln vs INR 49.61 bln year ago 

--Lupin FY25 consol net profit INR 32.82 bln vs INR 19.14 bln year ago 

--Lupin FY25 consol revenue INR 227.08 bln vs INR 200.11 bln year ago 

--Lupin to pay INR 12 per share dividend 

 

By P. Madhu Kumar

 

MUMBAI – Lupin Ltd. reported a slightly higher than expected consolidated net profit and consolidated revenue for the March quarter, driven by new product launches and a sharp improvement in operating margin. Its net profit more than doubled during the quarter as the rise in overall expenses was much slower.

 

The bottom line rose a whopping 114% to INR 7.73 billion, surpassing analysts' expectation of INR 7.43 billion. Lupin Ltd. released its financial results for the March quarter late on Wednesday after markets closed.

 

The higher profit for the quarter was driven by a sharp improvement in margin and lower tax outgo. The company's earnings before interest, tax, depriciation, and amortisation margin expanded by 381 basis points on year to 24.8% in the March quarter. Its EBITDA rose 34% on year to INR 13.78 billion. The company reported a tax outgo of INR 1.13 billion, compared to INR 1.29 billion a year ago.

 

The pharmaceutical major's top line for the quarter increased over 14% on year to 56.67 billion, slightly higher than the Street's expectation of INR 55.61 billion. More

 

Lupin's top line and bottom line rose on year but declined sequentially. The consolidated net revenue fell 1% and net profit slipped nearly 10% on quarter.

 

Sales in North America rose 19% on year and 6.6% sequentially to INR 22.62 billion. The company recieved seven abbreviated new drug application approvals from the US Food and Drug Administration during the quarter. It launched two new products in the March quarter and currently has 138 generic products in the US market.

 

Sales in India were INR 17.11 billion, up nearly 7% on year but down 11.4% sequentially. The company launched four new brands across therapies during the quarter. The Ahmedabad-based company's sales in other developed markets jumped 30% on year to INR 6.9 billion from the year-ago quarter. The global active pharmaceutical ingredient sales were INR 2.3 billion, down 10% on year and 19% on quarter. 

 

For the year ended March, sales in North America rose 16% to INR 83.95 billion and contributed 38% of the company's overall sales for FY25, making it the largest contributor. Sales in India contributed 34% to the overall sales and were at INR 75.77 billion, up 14%.

 

The company's research and development cost for the latest quarter rose 8% to INR 5.3 billon from INR 4.2 billion in the year-ago quarter. Lupin's total expenses rose 7% on year in the March quarter to 48.28 billion from INR 44.92 billion. At 0934 IST, shares of Lupin were at INR 2,079.70 on the National Stock Exchange, up 0.4%. The company had detailed its earnings after market hours Wednesday.  End

 

IST, or Indian Standard Time, is five-and-a-half hours ahead of GMT

 

Edited by Avishek Dutta

 

For users of real-time market data terminals, Informist news is available exclusively on the NSE Cogencis WorkStation.

 

Cogencis news is now Informist news. This follows the acquisition of Cogencis Information Services Ltd by NSE Data & Analytics Ltd, a 100% subsidiary of the National Stock Exchange of India Ltd. As a part of the transaction, the news department of Cogencis has been sold to Informist Media Pvt Ltd.

 

Informist Media Tel +91 (22) 6985-4000 

Send comments to feedback@informistmedia.com

 

© Informist Media Pvt. Ltd. 2025. All rights reserved.